Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and Hyper-CVAD in Ph+ ALL or CML Blast Phase
NCT01670084Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Dec 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by Mayo Clinic. Planned start Dec 2012; status: withdrawn.
02
Drugs
nilotinib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01670084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670084.